产品描述
| 溶解性 | DMSO ≥122mg/mL Water <1.2mg/mL Ethanol ≥10mg/mL |
| 存贮条件 | 储存温度-20°C |
| 应用 | An ATP-competitive inhibitor of tyrosine kinases including Flt-1, Flt-4, Met, and Ron. |
| 产品介绍 | Foretinib (GSK1363089)是一种ATP竞争性的HGFR和VEGFR抑制剂，作用于Met和KDR作用最强，IC50分别为0.4 nM和0.9 nM，对Ron， Flt-1/3/4， Kit， PDGFRα/β和Tie-2作用效果稍弱，对FGFR1和EGFR几乎没有抑制活性。 |
| 备注 | Foretinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase |
| 生化机理 | Foretinib is an ATP-competitive active site inhibitor of tyrosine kinases including Flt-1, Flt-4, Met, and Ron. |
| 别名 | N-[3-氟-4-[[6-甲氧基-7-[[3-(吗啉-4-基)丙基]氧]喹啉-4-基]氧]苯基]-N'-(4-氟苯基)环丙烷-1,1-二甲酰胺;XL880; GSK1363089; GSK089; EXEL-2880;N-[3-Fluoro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl]oxy]phenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide; N-[3-Fluoro-4-[[6-(methyloxy)-7-[[3-(morpholin-4-yl)propyl]oxy]quinolin-4-yl]oxy]phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide |
